Kantarjian H - Search Results

1

Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors.

Haddad FG, Kantarjian H. Haddad FG, et al. Among authors: kantarjian h. J Natl Compr Canc Netw. 2024 Feb;22(1):e237116. doi: 10.6004/jnccn.2023.7116. J Natl Compr Canc Netw. 2024. PMID: 38394773 Review.

2

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.

O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. O'Brien S, et al. Cancer. 2002 Apr 1;94(7):2024-32. doi: 10.1002/cncr.10436. Cancer. 2002. PMID: 11932905 Free article.

3

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.

Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantarjian HM, Stopeck AT. Giles FJ, et al. Cancer. 2003 Apr 15;97(8):1920-8. doi: 10.1002/cncr.11315. Cancer. 2003. PMID: 12673719 Free article. Clinical Trial.

4

Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.

Kantarjian H, O'Brien S, Cortes J, Giles F, Thomas D, Kornblau S, Shan J, Beth Rios M, Keating M, Freireich E, Talpaz M. Kantarjian H, et al. Cancer. 2003 Jul 1;98(1):81-5. doi: 10.1002/cncr.11477. Cancer. 2003. PMID: 12833459 Free article.

5

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.

Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Faderl S, Wierda W, Rios MB, Shan J, Cortes J. Kantarjian HM, et al. Cancer. 2005 Aug 15;104(4):777-80. doi: 10.1002/cncr.21235. Cancer. 2005. PMID: 15971197 Free article.

6

Trends in the management of chronic myelogenous leukemia.

Kantarjian H. Kantarjian H. J Natl Compr Canc Netw. 2005 Nov;3 Suppl 1:S41-5. J Natl Compr Canc Netw. 2005. PMID: 16280112 No abstract available.

7

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.

Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Rios MB, Shan J, Kantarjian HM. Cortes JE, et al. Cancer. 2006 Mar 15;106(6):1306-15. doi: 10.1002/cncr.21756. Cancer. 2006. PMID: 16463391 Free article.

8

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J. Quintás-Cardama A, et al. Among authors: kantarjian h. Cancer. 2007 Jan 15;109(2):248-55. doi: 10.1002/cncr.22398. Cancer. 2007. PMID: 17154172 Free article. Clinical Trial.

9

Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.

Kantarjian HM, Cortes J, Guilhot F, Hochhaus A, Baccarani M, Lokey L. Kantarjian HM, et al. Cancer. 2007 Apr 1;109(7):1365-75. doi: 10.1002/cncr.22523. Cancer. 2007. PMID: 17326047 Free article.

10

Current and emerging treatment options in chronic myeloid leukemia.

Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Jabbour E, et al. Cancer. 2007 Jun 1;109(11):2171-81. doi: 10.1002/cncr.22661. Cancer. 2007. PMID: 17431887 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,514 results

Search Page